Indiana Court of Appeals Vacates Workplace Threat
Indiana Court of Appeals Vacates Workplace Threat
Employee Claims Hobby Lobby Fired Her for Giving Birth
Employee Claims Hobby Lobby Fired Her for Giving Birth
Zillow Merges with Trulia for $3.5 Billion
Zillow Merges with Trulia for $3.5 Billion
Bribery Case Involving Wal-Mart Takes Interesting Turn
Bribery Case Involving Wal-Mart Takes Interesting Turn
Job Listings

Roche Doubles Alzheimer’s Test Group

facebooktwittergoogle_plusredditpinterestlinkedinmail

A Swiss drug manufacturer, Roche Holding AG, feels that it has taken the lead in the race to develop a drug that could alter the course of Alzheimer’s disease since many other companies suffered setbacks.  A clinical trial operated by the company has been doubled in size so its experimental drug known as gantenerumab can be tested in patients who have not been diagnosed with dementia yet.

“The playing field has changed dramatically and gantenerumab is now the most advanced monoclonal antibody in early Alzheimer’s and the next big news to read out in this space,” Luca Santarelli, Roche’s head of neuroscience, said in an interview with Yahoo News.

“We targeted this space four years ago and our trial started at the end of 2010, so we are way ahead,” Santarelli said.

The data from the study is not expected to be released until sometime in 2015. The trial, which has increased from 360 patients to 770 patients moves it into a final-stage Phase III. Roche hopes that the trial will show an effect because tests have shown that the drug being tested can help reduce amyloid plaques in the brain. These plaques are linked to the disease.

What

 job title, keywords

Where

 city, state, zip



Get JD Journal in Your Mail
Subscribe to our FREE daily news alerts and get the latest updates on the most happening events in the legal, business, and celebrity world. You also get your daily dose of humor and entertainment!!


Roche might be able to file for marketing approval with just one trial if the company’s results are incredibly strong. There are three other drugs being tested by Roche right now and they include crenezumab. This drug was picked by the U.S. government for a trial in Colombians who suffer from genetic mutations that cause Alzheimer’s in their 40s.

Roche Doubles Alzheimer's Test Group by
facebooktwittergoogle_plusredditpinterestlinkedinmail

Tagged: , , , ,

Posted by on September 7, 2012. Filed under Business News. You can follow any responses to this entry through the RSS 2.0. You can skip to the end and leave a response. Pinging is currently not allowed.

 

 

Job of the Day
ATTORNEY
USA-MO-Saint Louis

St. Louis-based commercial/industrial real estate company seeks attorney with 5 or more years experience .  Successful candidate must have experience negotiating and drafting purchase and sale co...